Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Peptidyl-prolyl cis-trans isomerase-like 3 (PPIL3) is a member of the cyclophilin family of peptidyl-prolyl isomerases, enzymes that catalyze the cis-trans isomerization of proline imide bonds in peptides and proteins[1][3][4]. This protein can function both as a catalyst for protein folding and as a molecular chaperone. PPIL3 directly interacts with the viral protein Apoptin in tumor cells, regulating Apoptin's cytoplasmic localization and, thereby, its apoptosis-inducing function in cancer cells[1]. Like other cyclophilins, PPIL3 may also play roles in pre-mRNA splicing, and its gene is alternatively spliced to produce different isoforms. Cyclophilin J (CYPJ), a synonym for PPIL3, is upregulated in certain cancers and has been proposed as a biomarker and potential therapeutic target[1][2]. The protein binds the immunosuppressant cyclosporine, though the physiological and clinical relevance of this interaction for PPIL3 specifically is not fully established[2].
Inhibition of isomerase activity (cyclosporine and derivatives)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Peptidyl-prolyl cis-trans isomerase-like 3 (PPIL3).